Profound Medical to Host Investor Call on March 13 to Discuss First Clinical Outcomes from Pivotal CAPTAIN Trial

summarizeSummary

Profound Medical announced an investor conference call on March 13, 2026, to discuss the first clinical outcomes from its pivotal CAPTAIN trial, which compares the TULSA Procedure to robotic radical prostatectomy.

check_boxKey Events

• CAPTAIN Trial Outcomes Presentation

  The first clinical outcomes from the Level 1 post-market CAPTAIN trial, comparing the TULSA Procedure™ with robotic radical prostatectomy, are scheduled for presentation at the 41st Annual European Association of Urology (EAU 2026) Congress on March 13, 2026.

• Investor Conference Call Scheduled

  Profound Medical will host an investor webinar on March 13, 2026, at 11:30 a.m. ET, where Dr. Laurence Klotz will review the CAPTAIN data and its clinical relevance, and management will discuss commercial implications and next steps for treatment guideline inclusion.

• Participation in ROTH Conference

  Management will also participate in one-on-one investor meetings at the 38th Annual Roth Conference from March 22-24, 2026.

auto_awesomeAnalysis

This 8-K announces a critical upcoming event for Profound Medical: the presentation and discussion of the first clinical outcomes from its Level 1 post-market CAPTAIN trial. This trial directly compares the TULSA Procedure™ to robotic radical prostatectomy for prostate cancer, making its results highly influential for market adoption and potential inclusion in treatment guidelines. Positive outcomes could significantly enhance the company's competitive position and drive future sales of its TULSA-PRO system. Investors will be closely watching the March 13 webinar for detailed data and management's commercial implications.